SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad ...

Research confirms that many men with nonmetastatic prostate cancer will not die of their disease once they received recommended treatment.

Background: Recent guidelines recommend against routine screening for prostate cancer, partly because of the risks associated with overtreatment of clinically indolent tumours. We aimed to determine ...

Overtreatment of men with prostate cancer and limited life expectancy (LE) has persisted in the era of active surveillance and worsened in some instances, according to a new study ...

Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, ...

Decipher Prostate Metastatic Genomic Classifier has been launched for use in patients whose prostate cancer has spread beyond the primary tumor, according to a news release from Veracyte, Inc. The ...

The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients and is the only gene expression test to be included in the most recent NCCN ...

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the ...